Wasatch Clinical Research

1. Vertex Pharmaceuticals Incorporated $1,570,111 7 payments
2. Lexicon Pharmaceuticals, Inc. $685,285 68 payments
3. Sanofi US Services Inc. $302,857 27 payments
4. Pfizer Inc. $269,284 5 payments
5. Biohaven Pharmaceuticals, Inc. $236,739 26 payments
6. Eli Lilly and Company $231,378 20 payments
7. Organon LLC $185,444 40 payments
8. American Regent $169,651 1 payment
9. Mylan Inc. $157,302 26 payments
10. AstraZeneca Pharmaceuticals LP $148,849 5 payments

1. A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain $916,224 3 payments
2. Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) $582,978 2 payments
3. Lx9211.1-204-Dpn $451,389 50 payments
4. A Multicenter Openlabel Study of Cp690550 in Subjects With Moderate to Severe Ulcerative Colitis $268,812 4 payments
5. Lx9211 $227,758 15 payments
6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc $178,044 6 payments
7. Tpx-100 $169,651 1 payment
8. A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $166,404 13 payments
9. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $138,259 22 payments
10. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $130,442 10 payments

1. Patient care $478,858 72 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.